{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:45:53Z","timestamp":1782708353531,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"crossref","award":["189220"],"award-info":[{"award-number":["189220"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11064-026-04766-y","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:14:15Z","timestamp":1777907655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex-Specific Differences in Amino Acids and Neurotransmitters in Multiple Sclerosis Patients Compared to Non-Neuroinflammatory Controls: A Retrospective Case-Control Study"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2725-1763","authenticated-orcid":false,"given":"Philip","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Glasmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-299X","authenticated-orcid":false,"given":"Anke","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3434-7283","authenticated-orcid":false,"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0978-1555","authenticated-orcid":false,"given":"J\u00fcrg","family":"Gertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"4766_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S0140-6736(16)30959-X","volume":"389","author":"WJ Brownlee","year":"2017","unstructured":"Brownlee WJ, Hardy TA, Fazekas F, Miller DH (2017) Diagnosis of multiple sclerosis: progress and challenges. Lancet 389:1336\u20131346. https:\/\/doi.org\/10.1016\/S0140-6736(16)30959-X","journal-title":"Lancet"},{"key":"4766_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/164_2020_407","volume":"273","author":"H Nishihara","year":"2022","unstructured":"Nishihara H, Engelhardt B (2022) Brain Barriers and Multiple Sclerosis: Novel Treatment Approaches from a Brain Barriers Perspective. Handb Exp Pharmacol 273:295\u2013329. https:\/\/doi.org\/10.1007\/164_2020_407","journal-title":"Handb Exp Pharmacol"},{"key":"4766_CR3","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/CON.0000000000001136","volume":"28","author":"M Ward","year":"2022","unstructured":"Ward M, Goldman MD (2022) Epidemiology and Pathophysiology of Multiple Sclerosis. Contin Minneap Minn 28:988\u20131005. https:\/\/doi.org\/10.1212\/CON.0000000000001136","journal-title":"Contin Minneap Minn"},{"key":"4766_CR4","doi-asserted-by":"publisher","first-page":"175628642110396","DOI":"10.1177\/17562864211039648","volume":"14","author":"H Wiendl","year":"2021","unstructured":"Wiendl H, Gold R, Berger T et al (2021) Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 14:17562864211039648. https:\/\/doi.org\/10.1177\/17562864211039648","journal-title":"Ther Adv Neurol Disord"},{"key":"4766_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41583-024-00823-z","volume":"25","author":"MS Woo","year":"2024","unstructured":"Woo MS, Engler JB, Friese MA (2024) The neuropathobiology of multiple sclerosis. Nat Rev Neurosci 25:493\u2013513. https:\/\/doi.org\/10.1038\/s41583-024-00823-z","journal-title":"Nat Rev Neurosci"},{"key":"4766_CR6","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.3390\/ijms23115877","volume":"23","author":"J Yang","year":"2022","unstructured":"Yang J, Hamade M, Wu Q et al (2022) Current and Future Biomarkers in Multiple Sclerosis. Int J Mol Sci 23:5877. https:\/\/doi.org\/10.3390\/ijms23115877","journal-title":"Int J Mol Sci"},{"key":"4766_CR7","doi-asserted-by":"publisher","first-page":"9207","DOI":"10.3390\/ijms26189207","volume":"26","author":"J Smusz","year":"2025","unstructured":"Smusz J, Mojsak P, Matys P et al (2025) Metabolomics in Multiple Sclerosis: Advances, Challenges, and Clinical Perspectives\u2014A Systematic Review. Int J Mol Sci 26:9207. https:\/\/doi.org\/10.3390\/ijms26189207","journal-title":"Int J Mol Sci"},{"key":"4766_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bj.2022.01.004","volume":"45","author":"Z Liu","year":"2022","unstructured":"Liu Z, Waters J, Rui B (2022) Metabolomics as a promising tool for improving understanding of multiple sclerosis: A review of recent advances. Biomed J 45:594\u2013606. https:\/\/doi.org\/10.1016\/j.bj.2022.01.004","journal-title":"Biomed J"},{"key":"4766_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40478-024-01864-2","volume":"12","author":"P Meier","year":"2024","unstructured":"Meier P, Glasmacher S, Salmen A et al (2024) Comparative targeted lipidomics between serum and cerebrospinal fluid of multiple sclerosis patients shows sex and age-specific differences of endocannabinoids and glucocorticoids. Acta Neuropathol Commun 12:160. https:\/\/doi.org\/10.1186\/s40478-024-01864-2","journal-title":"Acta Neuropathol Commun"},{"key":"4766_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/acschemneuro.2c00589","volume":"14","author":"E Akyuz","year":"2023","unstructured":"Akyuz E, Celik BR, Aslan FS et al (2023) Exploring the Role of Neurotransmitters in Multiple Sclerosis: An Expanded Review. ACS Chem Neurosci 14:527\u2013553. https:\/\/doi.org\/10.1021\/acschemneuro.2c00589","journal-title":"ACS Chem Neurosci"},{"key":"4766_CR11","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s00330-017-5064-9","volume":"28","author":"G Cao","year":"2018","unstructured":"Cao G, Edden RAE, Gao F et al (2018) Reduced GABA levels correlate with cognitive impairment in patients with relapsing-remitting multiple sclerosis. Eur Radiol 28:1140\u20131148. https:\/\/doi.org\/10.1007\/s00330-017-5064-9","journal-title":"Eur Radiol"},{"key":"4766_CR12","doi-asserted-by":"publisher","first-page":"e209543","DOI":"10.1212\/WNL.0000000000209543","volume":"103","author":"MA Madsen","year":"2024","unstructured":"Madsen MA, Pova\u017ean M, Wiggermann V et al (2024) Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis. Neurology 103:e209543. https:\/\/doi.org\/10.1212\/WNL.0000000000209543","journal-title":"Neurology"},{"key":"4766_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.neuroimage.2017.01.033","volume":"157","author":"JC Nantes","year":"2017","unstructured":"Nantes JC, Proulx S, Zhong J et al (2017) GABA and glutamate levels correlate with MTR and clinical disability: Insights from multiple sclerosis. NeuroImage 157:705\u2013715. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.01.033","journal-title":"NeuroImage"},{"key":"4766_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12974-024-03218-0","volume":"21","author":"C Otto","year":"2024","unstructured":"Otto C, Kalantzis R, K\u00fcbler-Weller D et al (2024) Comprehensive analysis of the cerebrospinal fluid and serum metabolome in neurological diseases. J Neuroinflammation 21:234. https:\/\/doi.org\/10.1186\/s12974-024-03218-0","journal-title":"J Neuroinflammation"},{"key":"4766_CR15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1001\/archneur.60.8.1082","volume":"60","author":"P Sarchielli","year":"2003","unstructured":"Sarchielli P, Greco L, Floridi A et al (2003) Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 60:1082\u20131088. https:\/\/doi.org\/10.1001\/archneur.60.8.1082","journal-title":"Arch Neurol"},{"key":"4766_CR16","doi-asserted-by":"publisher","first-page":"146589","DOI":"10.1016\/j.brainres.2019.146589","volume":"1732","author":"DA Sylvestre","year":"2020","unstructured":"Sylvestre DA, Slupsky CM, Aviv RI et al (2020) Untargeted metabolomic analysis of plasma from relapsing-remitting multiple sclerosis patients reveals changes in metabolites associated with structural changes in brain. Brain Res 1732:146589. https:\/\/doi.org\/10.1016\/j.brainres.2019.146589","journal-title":"Brain Res"},{"key":"4766_CR17","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1212\/NXI.0000000000000321","volume":"4","author":"P Villoslada","year":"2017","unstructured":"Villoslada P, Alonso C, Agirrezabal I et al (2017) Metabolomic signatures associated with disease severity in multiple sclerosis. Neurol Neuroimmunol Neuroinflammation 4:e321. https:\/\/doi.org\/10.1212\/NXI.0000000000000321","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"4766_CR18","doi-asserted-by":"publisher","first-page":"fcab240","DOI":"10.1093\/braincomms\/fcab240","volume":"3","author":"T Yeo","year":"2021","unstructured":"Yeo T, Probert F, Sealey M et al (2021) Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach. Brain Commun 3:fcab240. https:\/\/doi.org\/10.1093\/braincomms\/fcab240","journal-title":"Brain Commun"},{"key":"4766_CR19","doi-asserted-by":"publisher","first-page":"16271","DOI":"10.3390\/ijms242216271","volume":"24","author":"M \u017did\u00f3","year":"2023","unstructured":"\u017did\u00f3 M, Ka\u010der D, Vale\u0161 K et al (2023) Metabolomics of Cerebrospinal Fluid Amino and Fatty Acids in Early Stages of Multiple Sclerosis. Int J Mol Sci 24:16271. https:\/\/doi.org\/10.3390\/ijms242216271","journal-title":"Int J Mol Sci"},{"key":"4766_CR20","doi-asserted-by":"publisher","first-page":"118402","DOI":"10.1016\/j.biopha.2025.118402","volume":"190","author":"V Morozova","year":"2025","unstructured":"Morozova V, Pellegata D, Singer S et al (2025) Pharmacodynamic analyses of LAT1 inhibitors in vitro and in vivo by targeted metabolomics reveal target-independent effects. Biomed Pharmacother Biomedecine Pharmacother 190:118402. https:\/\/doi.org\/10.1016\/j.biopha.2025.118402","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"4766_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbi.2025.06.026","volume":"129","author":"CJ Kaufhold","year":"2025","unstructured":"Kaufhold CJ, Mani KK, Akbari Z, Sohrabji F (2025) Sex differences in neurological disorders: Insights from ischemic stroke, Parkinson\u2019s disease, and multiple sclerosis. Brain Behav Immun 129:335\u2013347. https:\/\/doi.org\/10.1016\/j.bbi.2025.06.026","journal-title":"Brain Behav Immun"},{"key":"4766_CR22","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1111\/jcmm.13767","volume":"22","author":"C Parrado-Fern\u00e1ndez","year":"2018","unstructured":"Parrado-Fern\u00e1ndez C, Blennow K, Hansson M et al (2018) Evidence for sex difference in the CSF\/plasma albumin ratio in ~\u200920 000 patients and 335 healthy volunteers. J Cell Mol Med 22:5151\u20135154. https:\/\/doi.org\/10.1111\/jcmm.13767","journal-title":"J Cell Mol Med"},{"key":"4766_CR23","doi-asserted-by":"publisher","first-page":"e038588","DOI":"10.1002\/alz.038588","volume":"16","author":"T Skillback","year":"2020","unstructured":"Skillback T, Blennow K, Zetterberg H et al (2020) Sex differences in CSF biomarkers for neurodegeneration and blood-brain barrier integrity. Alzheimers Dement 16:e038588. https:\/\/doi.org\/10.1002\/alz.038588","journal-title":"Alzheimers Dement"},{"key":"4766_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12987-015-0016-8","volume":"12","author":"G Wittmann","year":"2015","unstructured":"Wittmann G, Moh\u00e1csik P, Balkhi MY et al (2015) Endotoxin-induced inflammation down-regulates l-type amino acid transporter 1 (LAT1) expression at the blood\u2013brain barrier of male rats and mice. Fluids Barriers CNS 12:21. https:\/\/doi.org\/10.1186\/s12987-015-0016-8","journal-title":"Fluids Barriers CNS"},{"key":"4766_CR25","doi-asserted-by":"publisher","first-page":"108722","DOI":"10.1016\/j.pharmthera.2024.108722","volume":"263","author":"E Tiligada","year":"2024","unstructured":"Tiligada E, Stefanaki C, Ennis M, Neumann D (2024) Opportunities and challenges in the therapeutic exploitation of histamine and histamine receptor pharmacology in inflammation-driven disorders. Pharmacol Ther 263:108722. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108722","journal-title":"Pharmacol Ther"},{"key":"4766_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2045-8118-10-19","volume":"10","author":"U Kallweit","year":"2013","unstructured":"Kallweit U, Aritake K, Bassetti CL et al (2013) Elevated CSF histamine levels in multiple sclerosis patients. Fluids Barriers CNS 10:19. https:\/\/doi.org\/10.1186\/2045-8118-10-19","journal-title":"Fluids Barriers CNS"},{"key":"4766_CR27","doi-asserted-by":"publisher","first-page":"e200461","DOI":"10.1212\/NXI.0000000000200461","volume":"12","author":"M Kupjetz","year":"2025","unstructured":"Kupjetz M, Langeskov-Christensen M, Riemenschneider M et al (2025) Persons With Multiple Sclerosis Reveal Distinct Kynurenine Pathway Metabolite Patterns. Neurol Neuroimmunol Neuroinflammation 12:e200461. https:\/\/doi.org\/10.1212\/NXI.0000000000200461","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"4766_CR28","doi-asserted-by":"publisher","first-page":"149415","DOI":"10.1016\/j.brainres.2024.149415","volume":"1853","author":"M Kupjetz","year":"2025","unstructured":"Kupjetz M, Wences Chirino TY, Joisten N, Zimmer P (2025) Kynurenine pathway dysregulation as a mechanistic link between cognitive impairment and brain damage: Implications for multiple sclerosis. Brain Res 1853:149415. https:\/\/doi.org\/10.1016\/j.brainres.2024.149415","journal-title":"Brain Res"},{"key":"4766_CR29","doi-asserted-by":"publisher","first-page":"e200372","DOI":"10.1212\/NXI.0000000000200372","volume":"12","author":"A Staats Pires","year":"2025","unstructured":"Staats Pires A, Krishnamurthy S, Sharma S et al (2025) Dysregulation of the Kynurenine Pathway in Relapsing Remitting Multiple Sclerosis and Its Correlations With Progressive Neurodegeneration. Neurol Neuroimmunol Neuroinflammation 12:e200372. https:\/\/doi.org\/10.1212\/NXI.0000000000200372","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"4766_CR30","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1177\/1352458514533400","volume":"20","author":"AN Carvalho","year":"2014","unstructured":"Carvalho AN, Lim JL, Nijland PG et al (2014) Glutathione in multiple sclerosis: more than just an antioxidant? Mult Scler Houndmills Basingstoke Engl 20:1425\u20131431. https:\/\/doi.org\/10.1177\/1352458514533400","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"4766_CR31","doi-asserted-by":"publisher","first-page":"20240952","DOI":"10.1515\/med-2024-0952","volume":"19","author":"A Bogoje Raspopovi\u0107","year":"2024","unstructured":"Bogoje Raspopovi\u0107 A, Balta V, Vodopi\u0107 M et al (2024) The possible role of oxidative stress marker glutathione in the assessment of cognitive impairment in multiple sclerosis. Open Med Wars Pol 19:20240952. https:\/\/doi.org\/10.1515\/med-2024-0952","journal-title":"Open Med Wars Pol"},{"key":"4766_CR32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1023\/a:1021191729865","volume":"24","author":"R Agarwal","year":"1999","unstructured":"Agarwal R, Shukla GS (1999) Potential role of cerebral glutathione in the maintenance of blood-brain barrier integrity in rat. Neurochem Res 24:1507\u20131514. https:\/\/doi.org\/10.1023\/a:1021191729865","journal-title":"Neurochem Res"},{"key":"4766_CR33","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.jcbfm.9600267","volume":"26","author":"J-F Ghersi-Egea","year":"2006","unstructured":"Ghersi-Egea J-F, Strazielle N, Murat A et al (2006) Brain Protection at the Blood\u2013Cerebrospinal Fluid Interface Involves a Glutathione-Dependent Metabolic Barrier Mechanism. J Cereb Blood Flow Metab 26:1165\u20131175. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600267","journal-title":"J Cereb Blood Flow Metab"},{"key":"4766_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1471-4159.2008.05750.x","volume":"108","author":"M Markianos","year":"2009","unstructured":"Markianos M, Koutsis G, Evangelopoulos M-E et al (2009) Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. J Neurochem 108:158\u2013164. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05750.x","journal-title":"J Neurochem"},{"key":"4766_CR35","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1212\/WNL.0b013e3181a0fe3f","volume":"72","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Iacobaeus E, Khademi M et al (2009) Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 72:1322\u20131329. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a0fe3f","journal-title":"Neurology"},{"key":"4766_CR36","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1093\/brain\/awv209","volume":"138","author":"N Cawley","year":"2015","unstructured":"Cawley N, Solanky BS, Muhlert N et al (2015) Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain J Neurol 138:2584\u20132595. https:\/\/doi.org\/10.1093\/brain\/awv209","journal-title":"Brain J Neurol"},{"key":"4766_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cnp.2019.01.004","volume":"4","author":"R Lazo-Gomez","year":"2019","unstructured":"Lazo-Gomez R, Vel\u00e1zquez G, de LL-G, Mireles-Jacobo D, Sotomayor-Sobrino MA (2019) Mechanisms of neurobehavioral abnormalities in multiple sclerosis: Contributions from neural and immune components. Clin Neurophysiol Pract 4:39\u201346. https:\/\/doi.org\/10.1016\/j.cnp.2019.01.004","journal-title":"Clin Neurophysiol Pract"},{"key":"4766_CR38","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1002\/jnr.24977","volume":"99","author":"A Sood","year":"2021","unstructured":"Sood A, Preeti K, Fernandes V et al (2021) Glia: A major player in glutamate-GABA dysregulation-mediated neurodegeneration. J Neurosci Res 99:3148\u20133189. https:\/\/doi.org\/10.1002\/jnr.24977","journal-title":"J Neurosci Res"},{"key":"4766_CR39","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s11011-024-01418-4","volume":"39","author":"J-M Li","year":"2024","unstructured":"Li J-M, Bai Y-Z, Zhang S-Q (2024) Advances and challenges in serine in the central nervous system: physicochemistry, physiology, and pharmacology. Metab Brain Dis 39:1637\u20131647. https:\/\/doi.org\/10.1007\/s11011-024-01418-4","journal-title":"Metab Brain Dis"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04766-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-026-04766-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04766-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:25:00Z","timestamp":1782707100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-026-04766-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4766"],"URL":"https:\/\/doi.org\/10.1007\/s11064-026-04766-y","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study is in accordance with the declaration of Helsinki and was approved by the cantonal ethics committee of Bern (Project-ID: 2020\u201302164). All patients provided written informed consent for the collection, storage and usage of biological material and medical documentation for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All patients provided written informed consent for the collection, storage and usage of biological material and medical documentation for research purposes and publication of anonymised data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"148"}}